These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
23. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547 [TBL] [Abstract][Full Text] [Related]
24. Durvalumab for the treatment of urothelial carcinoma. Alsharedi M; Srivastava R; Elmsherghi N Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083 [TBL] [Abstract][Full Text] [Related]
25. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Kok VC Front Oncol; 2020; 10():268. PubMed ID: 32185135 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. Calmeiro J; Carrascal MA; Tavares AR; Ferreira DA; Gomes C; Cruz MT; Falcão A; Neves BM Pharmacol Res; 2021 Feb; 164():105309. PubMed ID: 33212291 [TBL] [Abstract][Full Text] [Related]
27. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461 [TBL] [Abstract][Full Text] [Related]
28. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016 [TBL] [Abstract][Full Text] [Related]
29. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. Garon EB Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470 [TBL] [Abstract][Full Text] [Related]
30. Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. Al-Showbaki L; Nadler MB; Desnoyers A; Almugbel FA; Cescon DW; Amir E J Cancer; 2021; 12(14):4372-4378. PubMed ID: 34093837 [No Abstract] [Full Text] [Related]
31. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. Shen X; Zhao B BMJ; 2018 Sep; 362():k3529. PubMed ID: 30201790 [TBL] [Abstract][Full Text] [Related]
32. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515 [TBL] [Abstract][Full Text] [Related]
33. Update on immunotherapy for renal cancer. Canales Rojas R Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067 [TBL] [Abstract][Full Text] [Related]
34. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061 [TBL] [Abstract][Full Text] [Related]
35. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways. Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698 [TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions. Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of cancer in 2012. Kirkwood JM; Butterfield LH; Tarhini AA; Zarour H; Kalinski P; Ferrone S CA Cancer J Clin; 2012; 62(5):309-35. PubMed ID: 22576456 [TBL] [Abstract][Full Text] [Related]